
Loading, please wait...

Loading, please wait...

Paras Healthcare Limited, which operates the popular 'Paras Health' brand, has filed its draft red herring prospectus (DRHP) with the capital markets regulator SEBI. The company aims to raise up to ₹1,800 crore through its initial public offering. Specifically, this upcoming Paras Healthcare IPO represents a major step in the hospital chain's expansion strategy across India. Investors and healthcare professionals are closely watching this development.
The proposed public issue is a mix of fresh capital and an offer-for-sale. According to the preliminary papers, the IPO comprises a fresh issue of equity shares aggregating up to ₹500 crore. Additionally, there is an Offer-For-Sale (OFS) of equity shares worth up to ₹1,300 crore by the selling shareholders. Consequently, the total issue size stands at ₹1,800 crore. Those selling shares in the OFS include promoter Dr. Dharminder Kumar Nagar and other key institutional investors. Therefore, the promoter will maintain a strong holding while allowing new investors to participate.
The Gurugram-based healthcare provider plans to deploy the proceeds strategically. First, the company will utilize ₹320.90 crore from the fresh issue to prepay or repay outstanding borrowings. Second, it plans to invest ₹54.10 crore in its wholly-owned subsidiary, PMHPL, to manage its debt obligations. The remaining amount will support general corporate purposes and IT infrastructure. Additionally, Paras Healthcare is on a strong growth trajectory. In fiscal year 2026, the company's revenue from operations reached ₹1,605.95 crore. Furthermore, its EBITDA stood at ₹335.58 crore during the same period, showing solid operational efficiency.
Currently, the hospital platform operates eight facilities across five states and one union territory. These locations include Haryana, Bihar, Uttar Pradesh, Rajasthan, Jharkhand, and Jammu & Kashmir. As of March 31, 2026, the network possesses an aggregate capacity of 2,211 beds. Specifically, the company plans to add a 300-bed hospital in Gurugram by fiscal year 2027. Additionally, it will establish a 500-bed hospital in Ludhiana by fiscal year 2028. Consequently, its total bed capacity will rise to 3,011 beds. This expansion will significantly enhance healthcare access in North India.
Q1: What is the total size of the Paras Healthcare IPO?
The total issue size of the IPO is up to ₹1,800 crore, which includes a fresh issue of ₹500 crore and an offer-for-sale (OFS) of ₹1,300 crore.
Q2: How does Paras Healthcare plan to use the IPO proceeds?
The company will use the fresh issue proceeds primarily for debt repayment of the parent company and its subsidiary, alongside general corporate purposes.
Q3: What is the current and projected bed capacity of Paras Health?
As of March 31, 2026, the company has 2,211 beds. However, with new hospitals in Gurugram and Ludhiana, capacity will rise to 3,011 beds by March 31, 2028.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Gurugram-based hospital network Paras Health plans to raise ₹1,800 crore through an IPO to fund expansion and repay outstanding borrowings....
4 months ago

Following Nigeria's first recorded Ebola case linked to regional travel, the Africa CDC has convened an emergency ministerial summit. This alert underscores critical clinical priorities for healthcare professionals, including differentiating early viral infection from malaria, implementing barrier nursing, and triage.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today